MedTrace Logo

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

NCT02119858 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-02-22

No results posted yet for this study

Summary

This clinical trial studies diffuse optical imaging with indocyanine green solution in imaging pelvic lymph nodes in patients with stage II prostate cancer undergoing surgery. Indocyanine green solution is a special dye that can help doctors see the lymph nodes and blood vessels during surgery when visualized under diffuse optical imaging. Indocyanine green solution may improve the ability to detect lymph nodes and may lead to improved accuracy of lymph node removal.

Conditions

  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer

Interventions

DRUG

indocyanine green solution

Given transperineally

OTHER

diffuse optical imaging

Undergo near infrared fluorescence imaging

PROCEDURE

robot-assisted laparoscopic surgery

Undergo robot-assisted laparoscopic radical prostatectomy

PROCEDURE

therapeutic lymphadenectomy

Undergo lymphadenectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Bertram Yuh · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-25
Primary Completion
2018-02-07
Completion
2018-02-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02119858 on ClinicalTrials.gov